Odyssey Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
51 Sleeper St, Boston, Massachusetts, 02...Phone Number
(617) 865-9628Website
www.odysseytx.comRevenue
<$5 MillionStock Symbol
ODTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company developing precision medicines for autoimmune and inflammatory diseases. The company focuses on targeting early immune signals that drive harmful inflammation, aiming to prevent disease before it progresses. Its research combines immunology, chemistry, and data science to create therapies designed to deliver deeper and longer lasting relief for patients.Explore more
Odyssey Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Odyssey Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Odyssey Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Odyssey Therapeutics is spiking on competitors!
Earning: See what the market has to say on Odyssey Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Odyssey Therapeutics has new funding data
Click to see if Odyssey Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Odyssey Therapeutics
Check if Odyssey Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Odyssey Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Odyssey Therapeutics
Compare insights from companies similar to Odyssey Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Odyssey Therapeutics
<$5M
51-200
Public
$979M
2021
AO
Anthony OpipariInterim Chief Medical Officer & Executive VP, Translational Medicine
Company Profile Activity
Activity Insights
Odyssey Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Odyssey Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Odyssey Therapeutics.
Odyssey Therapeutics financials insights
Gather financial insights about Odyssey Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$218M
2022
Series B
$168M
2023
Series C
$101M
2025
Series D
$213M
2026
IPO
$279M
Odyssey Therapeutics Tech Stack
A closer look at the technologies used by Odyssey Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Open Position
Earnings
Earnings, Finance
Hiring Plans
Odyssey Therapeutics is hiring in Medical & Health for the first time in 12 months. Areas of expertise include: Biostatistics, Life Sciences, Pharmacovigilance, Trial Master File, Medical Monitoring, Clinical Monitoring, and Clinical Research.
Hiring Plans
Hiring Plans
Hiring Plans
Odyssey Therapeutics News & Media
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
On August 4, Odyssey Therapeutics (NASDAQ:ODTX) reported its second-quarter financial results and gave investors a fresh look at where its lead autoimmune drug candidate stands. The clinical-stage biopharmaceutical company said it closed the quarter with $433.1 million in cash, enough to keep the lights on well into 2028, while its RIPK2 inhibitor OD-001 moves toward […]Odyssey Therapeutics to Participate in Upcoming Investor Conferences
Odyssey Therapeutics will participate in three upcoming global healthcare investor conferences this September, each featuring a fireside chat discussion.Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple...Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Odyssey Therapeutics
Sign Up For FreeTo access detailed company insights
Odyssey Therapeutics is a biotechnology company developing precision medicines for autoimmune and inflammatory diseases. The company focuses on targeting early immune signals that drive harmful inflammation, aiming to prevent disease before it progresses. Its research combines immunology, chemistry, and data science to create therapies designed to... Read More
